ATE529750T1 - Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target - Google Patents

Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target

Info

Publication number
ATE529750T1
ATE529750T1 AT06796239T AT06796239T ATE529750T1 AT E529750 T1 ATE529750 T1 AT E529750T1 AT 06796239 T AT06796239 T AT 06796239T AT 06796239 T AT06796239 T AT 06796239T AT E529750 T1 ATE529750 T1 AT E529750T1
Authority
AT
Austria
Prior art keywords
pdgf receptor
therapeutic target
autoantibodies against
pathological marker
erk1
Prior art date
Application number
AT06796239T
Other languages
English (en)
Inventor
Vittorio Enrico Avvedimento
Gabrielli Armando
Mariarosa Santillo
Ada Funaro
Michele Luchetti
Baroni Silvia Svegliati
Original Assignee
Vittorio Enrico Avvedimento
Gabrielli Armando
Mariarosa Santillo
Ada Funaro
Michele Luchetti
Baroni Silvia Svegliati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vittorio Enrico Avvedimento, Gabrielli Armando, Mariarosa Santillo, Ada Funaro, Michele Luchetti, Baroni Silvia Svegliati filed Critical Vittorio Enrico Avvedimento
Application granted granted Critical
Publication of ATE529750T1 publication Critical patent/ATE529750T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT06796239T 2005-07-28 2006-07-28 Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target ATE529750T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70337705P 2005-07-28 2005-07-28
PCT/IT2006/000587 WO2007013124A2 (en) 2005-07-28 2006-07-28 Stimulatory auto-antibodies to the pdgf receptor as pathology marker and therapeutic target

Publications (1)

Publication Number Publication Date
ATE529750T1 true ATE529750T1 (de) 2011-11-15

Family

ID=37683748

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06796239T ATE529750T1 (de) 2005-07-28 2006-07-28 Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target

Country Status (8)

Country Link
US (2) US20090221481A1 (de)
EP (1) EP1907851B1 (de)
JP (1) JP2009503493A (de)
KR (1) KR20080077347A (de)
CN (1) CN101517414A (de)
AT (1) ATE529750T1 (de)
CA (1) CA2616963A1 (de)
WO (1) WO2007013124A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008090213A1 (en) * 2007-01-25 2008-07-31 Mariarosaria Santillo Methods to diagnose an autoimmune disease and to identify and isolate stimulatory molecules
WO2012013813A1 (en) 2010-07-30 2012-02-02 Gianluca Moroncini Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof
WO2014011416A2 (en) * 2012-07-11 2014-01-16 Biomimetic Therapeutics, Llc Cell-based assay for neutralizing antibodies
WO2014016284A1 (en) * 2012-07-23 2014-01-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing scleroderma
HK1216428A1 (zh) * 2012-11-09 2016-11-11 辉瑞公司 血小板衍生生长因子b之特异性抗体及其组合物和用途
WO2020037378A1 (en) * 2018-08-24 2020-02-27 The Flinders University Of South Australia Detection of functional autoantibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926888T2 (de) * 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5268358A (en) * 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
CA2138932A1 (en) * 1993-12-28 1995-06-29 Masako Wagatsuma Mutant proteins of human dna topoisomerase i
JP3472048B2 (ja) * 1995-10-09 2003-12-02 鐘淵化学工業株式会社 自己免疫疾患の診断薬
ES2257446T3 (es) * 2000-10-17 2006-08-01 Besst-Test Aps Ensayo para detectar directamente un indicador de inflamacion en una muestra de fluido corporal.
JP3455782B2 (ja) * 2001-12-27 2003-10-14 学校法人慶應義塾 強皮症の診断薬

Also Published As

Publication number Publication date
US20090221481A1 (en) 2009-09-03
CA2616963A1 (en) 2007-02-01
US20120252037A1 (en) 2012-10-04
EP1907851B1 (de) 2011-10-19
KR20080077347A (ko) 2008-08-22
WO2007013124A2 (en) 2007-02-01
CN101517414A (zh) 2009-08-26
WO2007013124A3 (en) 2007-07-19
WO2007013124A8 (en) 2007-09-27
EP1907851A2 (de) 2008-04-09
JP2009503493A (ja) 2009-01-29

Similar Documents

Publication Publication Date Title
EP1692318A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von lungenkrebs
BRPI0510274B8 (pt) uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico
BRPI0519047A2 (pt) mÉtodo para a produÇço de um agente de contraste marcador ou agente terapÊutico marcador, agentes de contraste marcadores e uso de agentes de contraste marcadores ou de agentes terapÊuticos marcadores
BRPI0518307A2 (pt) mÉtodo e composiÇço de matÉria para tratar um indivÍduo tendo um cÂncer, kit, composiÇço farmacÊutica, mÉtodo para impregnar ou carregar um dispositivo implantÁvel de liberaÇço de droga, dispositivo implantÁvel de liberaÇço de droga, mÉtodo para avaliar a resposta de um indivÍduo tendo cÂncer a um tratamento usando um agonista de tlr3 ou selecionar um indivÍduo tendo um cÂncer que responde a um tratamento usando um agonista de tlr3, complexo, mÉtodo para determinar se um composto de teste É étil para o tratamento de cÂncer, e, uso de um agonista de tlr3
EP1723251A4 (de) In-vitro-testsystem zur prognose der verträglichkeit eines patienten gegenüber therapeutika
EP1583504A4 (de) Verfahren und zusammensetzungen für diagnose, prognose und behandlung von krebs
BR112022004986A2 (pt) Anticorpos anti-tnfr2 e métodos de uso
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
MX2011010353A (es) Composicion farmaceutica.
Maddali-Bongi et al. Impact of hand and face disabilities on global disability and quality of life in systemic sclerosis patients
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
EP1350085A4 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
EP2081435A4 (de) Hämmer der bruton-tyrosinkinase
EP2004230A4 (de) N-cadherin- und ly6 e:-ziele für die krebsdiagnose und -therapie
MX2009002471A (es) Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora.
EP1516049A4 (de) Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs
WO2006063093A3 (en) Methods for diagnosis and treatment of crohn's disease
DE602006014691D1 (de) DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN
EA201690004A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target
MY209272A (en) Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors
ES2619569T3 (es) Método de ensayo de infección o inflamación de las vías respiratorias inferiores
EP1608967A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties